AstraZeneca (AZN) Stock Forecast & Price Target

Compare

331 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Strong Buy

13 Buy

2 Hold

1 Sell

Based on 16 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

$215.93

▲(14.60% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $215.93 with a high forecast of $271.73 and a low forecast of $149.78. The average price target represents a 14.60% change from the last price of $188.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"136":"$136","170":"$170","204":"$204","238":"$238","272":"$272"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":271.726475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$271.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215.9298955245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$215.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":149.780935,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$149.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[136,170,204,238,272],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.73,208.96049807692307,214.19099615384616,219.4214942307692,224.6519923076923,229.88249038461538,235.11298846153846,240.34348653846155,245.5739846153846,250.8044826923077,256.03498076923074,261.2654788461538,266.4959769230769,{"y":271.726475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.73,204.6684535018846,205.60690700376924,206.54536050565383,207.48381400753846,208.42226750942308,209.3607210113077,210.2991745131923,211.23762801507692,212.17608151696155,213.11453501884617,214.05298852073076,214.9914420226154,{"y":215.9298955245,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.73,199.5800719230769,195.43014384615384,191.28021576923075,187.1302876923077,182.9803596153846,178.83043153846154,174.68050346153845,170.5305753846154,166.3806473076923,162.23071923076924,158.08079115384615,153.93086307692306,{"y":149.780935,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":150.346,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.565,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.204,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.042,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.956,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.453,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.864,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.225,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.474,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.674,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.73,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$271.73

Average Price Target$215.93

Lowest Price Target$149.78

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steve Scala

TD Cowen

$240

Buy

27.38%

Upside

Reiterated

03/18/26

AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Justin Smith

Bernstein

$14.09→$271.73

Buy

44.21%

Upside

Reiterated

03/18/26

Bernstein Remains a Buy on AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

$225.33

Buy

19.59%

Upside

Assigned

03/16/26

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

Seamus Fernandez

Guggenheim

$191.43→$212.08

Buy

12.56%

Upside

Reiterated

03/10/26

Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

$218.65

Buy

16.05%

Upside

Reiterated

03/10/26

AstraZeneca: Late‑Stage Pipeline Strength, Margin Expansion, and Undervalued Earnings Inflection Justify Buy Rating

Michael Leuchten

Jefferies

$198.82→$238.59

Buy

26.63%

Upside

Reiterated

03/06/26

Jefferies Remains a Buy on AstraZeneca (AZN)

Emmanuel Papadakis

Deutsche Bank

$152.43

Sell

-19.10%

Downside

Reiterated

03/05/26

Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

$200.28

Buy

6.30%

Upside

Reiterated

03/02/26

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

$109→$219

Buy

16.23%

Upside

Reiterated

03/02/26

AstraZeneca price target raised to $219 from $109 at Morgan StanleyAstraZeneca price target raised to $219 from $109 at Morgan Stanley

Matthew Weston

UBS

$216.06→$233.29

Buy

23.81%

Upside

Reiterated

02/25/26

UBS Remains a Buy on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

02/12/26

DZ BANK AG Remains a Hold on AstraZeneca (AZN)

Graham Parry

Citi

$225.33

Buy

19.59%

Upside

Reiterated

02/11/26

AstraZeneca (AZN) Gets a Buy from Citi

Sachin Jain

Bank of America Securities

$218.71

Buy

16.07%

Upside

Reiterated

02/10/26

AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside

James Gordon CFA

Barclays

$218.71

Buy

16.07%

Upside

Reiterated

02/10/26

Barclays Remains a Buy on AstraZeneca (AZN)

David Evans

Kepler Capital

$149.78

Hold

-20.51%

Downside

Reiterated

02/10/26

AstraZeneca (AZN) Receives a Hold from Kepler Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steve Scala

TD Cowen

$240

Buy

27.38%

Upside

Reiterated

03/18/26

AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Justin Smith

Bernstein

$14.09→$271.73

Buy

44.21%

Upside

Reiterated

03/18/26

Bernstein Remains a Buy on AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

$225.33

Buy

19.59%

Upside

Assigned

03/16/26

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

Seamus Fernandez

Guggenheim

$191.43→$212.08

Buy

12.56%

Upside

Reiterated

03/10/26

Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

$218.65

Buy

16.05%

Upside

Reiterated

03/10/26

AstraZeneca: Late‑Stage Pipeline Strength, Margin Expansion, and Undervalued Earnings Inflection Justify Buy Rating

Michael Leuchten

Jefferies

$198.82→$238.59

Buy

26.63%

Upside

Reiterated

03/06/26

Jefferies Remains a Buy on AstraZeneca (AZN)

Emmanuel Papadakis

Deutsche Bank

$152.43

Sell

-19.10%

Downside

Reiterated

03/05/26

Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

$200.28

Buy

6.30%

Upside

Reiterated

03/02/26

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

$109→$219

Buy

16.23%

Upside

Reiterated

03/02/26

AstraZeneca price target raised to $219 from $109 at Morgan StanleyAstraZeneca price target raised to $219 from $109 at Morgan Stanley

Matthew Weston

UBS

$216.06→$233.29

Buy

23.81%

Upside

Reiterated

02/25/26

UBS Remains a Buy on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

02/12/26

DZ BANK AG Remains a Hold on AstraZeneca (AZN)

Graham Parry

Citi

$225.33

Buy

19.59%

Upside

Reiterated

02/11/26

AstraZeneca (AZN) Gets a Buy from Citi

Sachin Jain

Bank of America Securities

$218.71

Buy

16.07%

Upside

Reiterated

02/10/26

AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside

James Gordon CFA

Barclays

$218.71

Buy

16.07%

Upside

Reiterated

02/10/26

Barclays Remains a Buy on AstraZeneca (AZN)

David Evans

Kepler Capital

$149.78

Hold

-20.51%

Downside

Reiterated

02/10/26

AstraZeneca (AZN) Receives a Hold from Kepler Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

xxx

Success Rate

15/21 ratings generated profit

Average Return

+4.16%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.16% per trade.

1 Year

Matthew WestonUBS

Success Rate

36/38 ratings generated profit

Average Return

+18.02%

reiterated a buy rating 23 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +18.02% per trade.

2 Years

xxx

Success Rate

20/21 ratings generated profit

Average Return

+27.80%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +27.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 34 Buy Ratings, 2 Hold Ratings, and 5 Sell Ratings. AZN average Analyst price target in the past 3 months is 215.93.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is $2.51 with a range of $2.37 to $2.77. The previous quarter’s EPS was $2.12. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is $14.71B with a range of $14.34B to $15.30B. The previous quarter’s sales results were $15.48B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 215.93.

What is AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 14.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AZN a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s price target?

The average price target for AstraZeneca PLC is 215.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $271.73 ,the lowest forecast is $149.78. The average price target represents 14.60% Increase from the current price of $188.42.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of AZN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZN) Stock Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Detailed List of Analyst Forecasts